Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up

European Psychiatry

Volumn 27, Issue 1, 2012, Pages 33-42

  Schoepf, D ^a   Potluri, R ^b   Uppal, H ^c   Natalwala, A ^d   Narendran, P ^c   Heun, R ^e  

^a UNIVERSITY OF BONN   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

Co morbidity; Diabetes mellitus; Epidemiology; Mortality; Schizophrenia

Indexed keywords

ADULT; AGE; ARTICLE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA;

AGED; CASE-CONTROL STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; ENGLAND; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 84655169890     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.02.009     Document Type: Article

References (61)

1. Alberti K.G., Zimmet P. The metabolic syndrome: time to reflect. Curr Diab Rep 2006, 6(4):259-261.
2. Aleman A., Kahn R.S., Selton J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003, 60:565-571.
3. Ali S., Stone M.A., Peters J.L., Davies M.J., Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006, 23(11):1165-1173.
4. Auquier P., Lançon C., Rouillon F., Lader M., Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006, 15(12):873-879.
5. Bertram M.Y., Vos T. Quantifying the duration of pre-diabetes. Aust N Z J Public Health 2010, 34(3):311-314.
6. Bhugra D., Leff J., Mallet R., Der G., Gorridan B., Budge S. Incidence and outcome of schizophrenia in whites, African Caribbean's and Asians in London. Psychol Med 1997, 27:791-798.
7. Bottlender R., Strauss A., Moller H.J. Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand 2000, 101:153-160.
8. Bottlender R., Jager M., Groll C., Strauss A., Moller H.J. Deficit states in schizophrenia and their association with the length of illness and gender. Eur Arch Psychiatry Clin Neurosci 2001, 251:272-278.
9. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
10. Capasso R.M., Lineberry T.W., Bostwick J.M., et al. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res 2008, 98:287-294.
11. Carney C.P., Jones L., Woolson R.F. Medical co-morbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006, 21:1133-1137.
12. Carral F., Olveira G., Aguilar M., et al. Hospital discharge records underreport the prevalence of diabetes in inpatients. Diabetes Res Clin Pract 2003, 59:145-151.
13. Cimpean D., Torrey W.C., Green A.L. Schizophrenia and co-occurring general medical illness. Psychiatr Ann 2005, 35:71-81.
14. Citrome L., Jaffe A., Levine J., Allingham B., Robinson J. Relationship between antipsychotic treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004, 55:1006-1013.
15. Citrome L., Blonde L., Damatarca C. Metabolic issues in patients with severe mental illness. South Med J 2005, 98(7):715-720.
16. Dickstein K., Cohen Solal A., et al. ESC Guidelines fort the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 2009, 29(19):2388-2442.
17. Druss B.G., Bradford D.W., Rosenheck R.A., Radford M.U., Krumholz H.M. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000, 283:506-511.
18. El-Mallah P. Evolving self-care in individuals with schizophrenia and diabetes mellitus. Arch Psychiatr Nurs 2006, 20:55-64.
19. George L.M., Maddock K. Accuracy of hospital activity notifications for infectious diseases. Br Med J 1979, 1:1332-1339.
20. Goff D.C., Cather C., Evins A.E., et al. Medical morbidity and mortality in schizophrenia: guideline for psychiatrist. J Clin Psychiatry 2005, 66:183-194.
21. Goldner E.M., Hsu L., Waraich P., Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002, 47:833-843.
22. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
23. Hill A. The environment and disease: association or causation. Proc R Soc Med 1965, 58:295-330.
24. Holt R.I.G. Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br J Psychiatry 2004, 184(Supplement):55-63.
25. Holt R.I.G., Peveler R.C., Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004, 21:531-566.
26. Iacovides A., Siamouli M. Co-morbid mental and somatic disorders: an epidemiological perspective. Curr Opin Psychiatry 2008, 21:417-421.
27. International Diabetes and Federation. Diabetes Atlas. International Diabetes Federation; 2003.
28. Jeremias A., Kaul S., et al. The impact of revascularisation on mortality in patients with non-acute coronary artery disease. Am J Med 2009, 122(2):151-161.
29. Joshy G., Dunn P., Fisher M., Lawrenson R. Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission rate for renal complications, and incidence of end-stage renal disease and renal death. Diabetologia 2009, 52(8):1474-1478.
30. Joss N., Patel R., Paterson K., Simpson K., Perry C., Stirling C. Anaemia is common and predicts mortality in diabetic nephropathy. QJM 2007, 100(10):641-647.
31. Kamalesh M., Cleophas T.J. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J Card Fail 2009, 15(4):305-309.
32. Knol M.J., Twisk J.W., Beekman A.T., Heine R.J., Snoek F.J., Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006, 49(5):837-845.
33. Kornum J.B., Thomson R.W., Riis A., et al. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007, 30:2251-2257.
34. Kreyenbuhl J., Dickerson F.B., Medoff D.R., et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes mellitus and serious mental illness. J Nerv Ment Dis 2006, 194:404-410.
35. Laaksonen M.A., Knekt P., Rissanen H., Härkänen T., Virtala E., Marniemi J., et al. The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts. Eur J Epidemiol 2010, 25(2):115-124.
36. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333.
37. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: speculation on pathogenesis, pathophysiology, and therapeutic options. Biol Psychiatry 2001, 50:884-897.
38. Makikyro T., Karvonen J.T., Hakko H., et al. Co-morbidity of hospital-treated psychiatric and physical disorders with spezial reference of schizophrenia: a 28-year follow-up of the 1996 northern Finnland general population birth cohort. Public health 1998, 112:221-228.
39. Meeuwisse-Pasterkamp S.H., van der Klauw M.M., Wolffenbuttel B.H. Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Rev Cardiovasc Ther 2008, 6(3):323-341.
40. Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31(12):2383-2390.
41. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996, 37:68-73.
42. Murphy G.M., Lim K.O., Wienecke M., et al. No neuropathology evidence for an increased frequency of Alzheimer's disease among elderly schizophrenics. Biol Psychiatry 1998, 43:205-209.
43. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychoatry 1991, 36:239-245.
44. NHS strategic tracing service. Better Information for health, where and when it's needed-NHS Connecting for Health; 2009.
45. Osby U., Correia N., Brandt L., Ekbom A., Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45(1-2):21-28.
46. Phung T.K., Andersen B.B., Høgh P., Kessing L.V., Mortensen P.B., Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007, 24(3):220-228.
47. Prohovnik I., Dwork A.J., Kaufman M.A., Wilson N. Alzheimer-type neuropathology in elderly schizophrenia patients. Schizophr Bull 1993, 19:805-816.
48. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160(2):284-289.
49. Ryan F.A., Majumdar S.R., Blitz S., Rowe B.H., Romney J., Marrie T.J. The realtion between hyperglycemia and outcomes in 2471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005, 28(4):810-815.
50. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008, 117(5):342-347.
51. Simpson J.C., Tsuang M.T. Mortality among patients with schizophrenia. Schizophr Bull 1996, 22:485-499.
52. Sirris S.G. Depression in schizophrenia: perspective in the era of atypical antipsychotic agents. Am J Psychiatry 2000, 157:1379-1389.
53. Smith M., Hopkins D., Peveler R.C., Holt R.I.G., Woodward M., Ismail K. First v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008, 192:406-411.
54. Stirban A.O., Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 2008, 31(Suppl.2):215-221.
55. Tandom R., Keshavan M.S., Nasrallah H.A. Schizophrenia, just the facts: what we know in 2008: 2 epidemiology and aetiology. Schizophr Res 2008, 102:1-18.
56. Taylor D.C. Schizophrenia and epilepsies: why? when? how?. Epilepsy Behav 2003, 4:474-482.
57. Ubink-Veltmaat L.J., Bilo H.J., Groenier K.H., et al. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003, 18(8):793-800.
58. Weber N.S., Cowan D.N., Millikan A.M., Niebuhr D.W. Psychiatric and general medical conditions co-morbid with schizophrenia in the national hospital discharge survey. Psychiatr Serv 2009, 60:1059-1067.
59. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. World Health Organisation; 1999.
60. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
61. Young J.K., Foster D.A. Cardiovascular procedures in mental disorders. JAMA 2000, 283(24):3198-3199.